Fulgent Genetics Reports Q1 2026 Financial Results: Key Details for Investors

Overview

Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-driven company with a dual focus on laboratory services and therapeutic development, has released its financial results for the first quarter ended March 31, 2026. The company remains steadfast in its revenue guidance for the full fiscal year and has executed a substantial stock repurchase program, signaling confidence in its long-term prospects.

Key Financial Highlights

• Revenue: \$71.1 million for Q1 2026, compared to \$73.5 million in Q1 2025 (a slight year-over-year decrease).
• GAAP Gross Profit: \$21.5 million (gross margin of 30.2%), down from \$28.3 million in the prior year (gross margin of 38.6%).
• Non-GAAP Gross Profit: \$23.0 million (non-GAAP gross margin of 32.3%), versus \$30.1 million (41.0%) in Q1 2025.
• GAAP Net Loss: \$(24.8) million, or \$(0.80) per share, compared to a loss of \$(11.5) million, or \$(0.37) per share, in Q1 2025.
• Non-GAAP Net Loss: \$(11.0) million, or \$(0.36) per share, compared to non-GAAP net income of \$1.2 million, or \$0.04 per share, in Q1 2025.
• Adjusted EBITDA: \$(15.2) million, down from \$(2.9) million in Q1 2025.
• Cash Position: Ended Q1 2026 with \$604.7 million in cash, cash equivalents, restricted cash, and investments in marketable securities (excluding an anticipated \$106 million tax refund).
• Stock Repurchase: Repurchased approximately 2.6 million shares in Q1 2026, utilizing \$40.1 million in cash.

Operational and Strategic Developments

• The laboratory services segment showed stability and delivered “solid results” despite a modest revenue decline.
• Significant progress was reported in the company’s therapeutic development pipeline, with both clinical candidates, FID-007 and FID-022, advancing. Notably, Fulgent will present Phase 2 data for FID-007 at the 2026 ASCO Annual Meeting.
• Management expressed continued confidence in the company’s fundamentals and long-term business strategy, as evidenced by the robust execution of the stock repurchase program.

Updated Guidance and Outlook for 2026

• Revenue Guidance: Maintained at approximately \$350 million for the full year 2026.
• Non-GAAP Loss: Now expected to be approximately \$(46.0) million, or \$(1.59) per share, reflecting the impact of the stock repurchase program.
• Cash Balance: Expected to be around \$636 million at year-end, assuming receipt of the \$106 million tax refund, \$12 million in capital purchases, \$26 million in therapeutic development spending, and no further repurchases.
• Gross Margins: Expected to normalize and improve in the second half of 2026.

Note: The cash guidance assumes no further share repurchases and is subject to variability from potential M&A activity, tax refund timing, and other factors.

Balance Sheet Snapshot (as of March 31, 2026)

• Total Assets: \$1.16 billion
• Total Stockholders’ Equity: \$1.04 billion
• Accounts Receivable: \$69.3 million
• Property, Plant & Equipment: \$116.3 million
• Other Assets: \$366.2 million
• Accounts Payable, Accrued and Other Liabilities: \$112.2 million

Non-GAAP Metrics and Adjustments

Fulgent provides several non-GAAP financial measures to better reflect underlying business performance. These adjustments include amortization of intangible assets, equity-based compensation, acquisition-related costs (including one-time banker, legal, due diligence, and severance expenses), and non-GAAP tax effects. Management underscores that these items are not necessarily unusual or non-recurring, but are excluded to focus on core operating results. Investors should be aware that non-GAAP metrics may not be comparable with those of other companies.

Risks and Forward-Looking Statements

The company’s outlook is subject to several risks and uncertainties, including but not limited to:

• Volatility in revenue and customer concentration risks, as revenue can depend on a small number of large customers.
• Integration risks and expected benefits from recent acquisitions (Bako Diagnostics and StrataDx).
• Timing and collectability of third-party reimbursements.
• Regulatory compliance and evolving healthcare laws.
• Success and timing of clinical development efforts.
• Market adoption of new tests and maintenance of competitive turnaround times.
• Ability to obtain expected tax refunds and protect intellectual property.
• Potential for further M&A activity or unplanned cash expenditures.

Shareholder-Important and Price-Sensitive Items

• Share Repurchase Program: The repurchase of 2.6 million shares and reduction of shares outstanding should be noted as it can have a direct impact on EPS calculations and share value.
• Therapeutic Pipeline Progress: The advancement and upcoming ASCO presentation of FID-007 could be a positive catalyst if clinical data are compelling.
• Cash and Tax Refund: Cash levels remain strong but are partially dependent on a delayed \$106 million tax refund. Any further delay or failure to collect could impact liquidity.
• Downward Trend in Gross Margin and Profitability: Both GAAP and non-GAAP profitability metrics show a significant year-over-year decline, which could concern shareholders if not reversed in upcoming quarters.
• Guidance Maintained Despite Losses: The company’s ability to maintain revenue guidance and project a cash-positive year-end despite operational losses may reassure investors, depending on execution.

Conclusion

Fulgent Genetics’ Q1 2026 report presents a mixed picture: while revenues and margins have softened, the company remains well-capitalized, continues to invest in R&D, and is actively managing its capital structure through share repurchases. Investors should closely monitor progress in the therapeutic pipeline (especially FID-007), the realization of anticipated tax refunds, and the normalization of gross margins in the second half of the year. The company’s strategic actions and clinical milestones could represent significant share price catalysts in 2026.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions. Fulgent Genetics’ actual results and future performance are subject to risks and uncertainties as described above and in the company’s filings with the SEC.

View Fulgent Genetics, Inc. Historical chart here